US Latinos have more unfavourable metabolic and body fat changes on HIV drugs

Kelly Safreed-Harmon
Published: 16 January 2009

A US study comparing metabolic and body composition changes in Latinos, whites and African-Americans after they initiated antiretroviral therapy found that Latinos had greater increases than the other two groups in glucose and insulin resistance, and were more likely to have lipoatrophy. The study, presented in the January 1st edition of the Journal of Acquired Immune Deficiency Syndromes, controlled for numerous factors, leading the authors to conclude that their findings were indicative of inherent racial/ethnic differences.

Antiretroviral therapy has long been associated with problematic changes in glucose and lipid metabolism and in body composition. However, it is difficult to ascertain the effects of particular drugs and drug combinations, in part because of the large number of factors that may contribute to the metabolic and body fat changes occurring in HIV-positive people. HIV itself appears to affect metabolic functioning independently of treatment. Also, aging is associated with metabolic and body fat changes, which means that some of the observed problems in HIV-positive people who are living much longer as a result of effective treatment may be related to the aging process.

The study analysed data from a subset of participants in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) study, which randomised antiretroviral-naive people to three treatment arms. FIRST study participants who enrolled in a related metabolic study were asked to name the racial/ethnic group that best fitted them. Among the 422 metabolic study participants, 412 identified as either African-American, Latino or white; 398 of these people met the selection criteria for the substudy investigating racial/ethnic differences.

The cohort of 398 included 243 African-Americans, 43 Latinos, and 112 whites. The group was 22% female, and 87% of females were African-American. There was an overall mean age of 38.

When the researchers compared the metabolic and body composition changes of African-Americans, Latinos and whites, they controlled for age, gender, hepatitis C status, CD4 cell count, viral load level, prior AIDS status and body mass index. They also controlled for cumulative time on ten antiretroviral drugs: indinavir (Crixivan), nelfinavir (Viracept), ritonavir (Norvir), efavirenz (Sustiva), nevirapine (Viramune), abacavir (Ziagen), ddI (didanosine, Videx), 3TC (lamivudine, Epivir), d4T (stavudine, Zerit) and AZT (zidovudine, Retrovir).

The most striking finding was that Latinos had more unfavorable glucose metabolism changes than either Africa-Americans or whites. Latinos had a significantly greater rate of increase in glucose levels than members of the other two groups, as well as a significantly greater rate of increase in insulin resistance levels (glucose: Latino vs African-American, p < 0.01, Latino vs white, p < 0.01; insulin resistance: Latino vs African-American, p < 0.01, Latino vs white, p = 0.01).

Latinos also differed from African-Americans and whites on some measures of body composition. Latinos had a greater mean loss in waist subcutaneous tissue area, as well as a higher rate of fat loss. They had a greater mean loss in mid-arm subcutaneous tissue area.

The authors point out that in the United States, Hispanics have the highest rates of metabolic syndrome and diabetes. People with metabolic syndrome, a cluster of conditions including elevated glucose levels and excess abdominal fat, are at increased risk of diabetes, stroke and heart disease.

The analysis also showed that African-Americans had smaller increases in triglyceride levels than Latinos or whites, as well as lower rates of increase. The authors again relate this to findings in the general population, observing that African-Americans may have an inherently lower risk than whites of developing hypertriglyceridemia.

Nonetheless, all three groups experienced increases in triglyceride levels. They all had increases in HDL cholesterol and decreases in LDL cholesterol as well.

The authors conclude, “Changes over time in body composition and the more unfavorable metabolic parameters observed among the Latinos compared with the African-Americans and whites in our study may reflect not only the impact of HIV infection and [antiretroviral therapy] but also different genetic predisposition.” They call for efforts to increase understanding of the clinical implications of these findings.

Reference

Gilbert C et al. Racial differences in changes of metabolic parameters and body composition in antiretroviral therapy-naive persons initiating antiretroviral therapy. J Acquir Immune Defic Syndr 50: 44 – 53, 2009.